Previous 10 | Next 10 |
COPENHAGEN, Denmark, March 14, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-powered immunotherapies, today announced that the company will present ...
Evaxion Biotech ( EVAX ) Pantherna Therapeutics reported preclinical data related to their mRNA vaccine for tumors. The companies said preclinical data showed that tumor neoantigens identified by Evaxion's AI platform PIONEER drive a strong immune response and lead to complete i...
COPENHAGEN, Denmark and HENNIGSDORF, Germany, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-powered immunotherapies and Pantherna Therapeut...
The U.S. Food and Drug Administration (FDA) granted fast track designation to Evaxion Biotech's ( EVAX ) personalized cancer immunotherapy EVX-01, in combination with Merck's ( NYSE: MRK ) Keytruda. In December 2022, Evaxion received FDA approval to proceed with a pha...
COPENHAGEN, Denmark, Jan. 19, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies, today announced that the U.S. Food and Drug Admi...
COPENHAGEN, Denmark, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies, today announced that the U.S. Food and Drug Admi...
Danish biotech Evaxion Biotech ( EVAX ) announced Friday that the FDA greenlighted its request to conduct a Phase 2b trial for its cancer immunotherapy EVX-01 in combination with Merck’s ( MRK ) checkpoint inhibitor Keytruda targeting patients with metastatic melanoma. The Amer...
COPENHAGEN, Denmark, Dec. 15, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies, today announced that they expect to present...
Evaxion Biotech ( EVAX ) signed an agreement with ExpreS 2 ion Biotech's affiliate ExpreS 2 ion Biotechnologies to jointly develop a novel cytomegalovirus (CMV) vaccine candidate. CMV is a common virus and a healthy person's immune system usually keeps the virus from causing i...
HØRSHOLM, Denmark, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies, today announces that the Company has signed a...
News, Short Squeeze, Breakout and More Instantly...
Central AI-Immunology™ Building Block: Evaxion’s proprietary in-house developed building block, EvaxMHC, is used across the AI-Immunology™ platform Improved Performance: Utilizing a state-of-the-art novel deep-learning framework as well as training on public and...
COPENHAGEN, Denmark, July 03, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today issued the following letter to shareholders...
Positive Feedback Received: An International Preliminary Report on Patentability (IPRP) indicates promising prospects for obtaining granted patents and protecting the invention Unique Attributes and Inventiveness: The feedback highlights the distinct and inventive nature of all rele...